Compared side by side

Tirzepatide vs cagrilintide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are weekly shots, on different hormones: tirzepatide activates the GLP-1 and GIP receptors, and cagrilintide is a long-acting analogue of amylin, the fullness hormone the pancreas releases with insulin, which promotes fullness and slows stomach emptying. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; cagrilintide isn’t approved on its own, and the crowd mostly runs it beside a GLP-1 drug. In trials on its own, cagrilintide’s higher doses led to about 10–12% weight loss, and tirzepatide’s 15 mg up to 22.5% at 72 weeks (SURMOUNT-1).

Side by side

ComparedTirzepatideCagrilintide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asMounjaro, Zepbound, LY3298176Cagri, AM833, NNC0174-0833
What it isThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).A long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot.
How it worksDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.Long-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema.
Commonly reportedVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).Feeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own.
Studied rangeFDA label: 2.5–15 mg, starting dose 2.5 mg.Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
How oftenWeeklyWeekly
Half-life~5 days (FDA label)~1 week (measured in people: 159–195 hours in a phase 1b trial)
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.Trials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigueNausea, constipation, diarrhea, injection-site reactions

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide or cagrilintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Tirzepatide

  • Day 1–28 · 2.5 mg Getting your gut acclimated
  • Day 29–56 · 5 mg First therapeutic dose — weight drops
  • Day 57–112 · 7.5 mg Dual agonism in full effect
  • Day 113–168 · 12.5 mg Max titration reached
  • Day 169–504 Weeks 24 to 72: where most people plateau
  • Day 365+ A maintenance medication, not a course

Every card for tirzepatide, with its sources

Cagrilintide

  • Day 1–28 · 0.25 mg The 0.25 mg start
  • Day 29–364 · 0.5 mg 0.5 mg, the second step
  • Day 57–364 · 1 mg 1 mg, the middle step
  • Day 85–364 · 1.7 mg 1.7 mg, the step before 2.4 mg
  • Day 113+ · 2.4 mg 2.4 mg, the phase 3 dose

Every card for cagrilintide, with its sources

Together or one or the other

Tirzepatide and cagrilintide are a common stack: cagrilintide lists tirzepatide among its common stacks.

Animal · Cagrilintide

With retatrutide or tirzepatide: the crowd's stacks

Cagrilintide beside retatrutide or tirzepatide is a common crowd stack, on the same logic as CagriSema. No trial in people has tested these pairs; in obese rats, cagrilintide plus retatrutide lost more weight than either alone.

Questions people ask

How long do tirzepatide and cagrilintide last?

The half-life of tirzepatide is ~5 days (FDA label). The half-life of cagrilintide is ~1 week (measured in people: 159–195 hours in a phase 1b trial).

How often are tirzepatide and cagrilintide taken?

Tirzepatide: weekly. Route: SubQ injection. Cagrilintide: weekly. Route: SubQ injection.

How are tirzepatide and cagrilintide dosed in research?

The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The research range for cagrilintide is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of tirzepatide and cagrilintide?

For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For cagrilintide: nausea, constipation, diarrhea, injection-site reactions.

Are tirzepatide and cagrilintide taken together?

Tirzepatide and cagrilintide are a common stack: cagrilintide lists tirzepatide among its common stacks. Cagrilintide beside retatrutide or tirzepatide is a common crowd stack, on the same logic as CagriSema. No trial in people has tested these pairs; in obese rats, cagrilintide plus retatrutide lost more weight than either alone.

Each one in full

Track it in the app

PepVault for iPhone

Taking tirzepatide or cagrilintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo